newsfilter
← Latest News
GlobeNewswire·

Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates

Granted Third Breakthrough Therapy Designation (BTD) for Repotrectinib for the treatment of patients with ROS1-positive Metastatic NSCLC who have been Previously Treated with One ROS1 TKI and who have not Received Prior Platinum-Based Chemotherapy Repo